|  |  |  |
| --- | --- | --- |
| 09-82918_logo_E_RGB | **International Narcotics Control Board** | **FORM B/P** Updated: July 2020 |
|  | | |

**ASSESSMENT OF ANNUAL MEDICAL AND SCIENTIFIC REQUIREMENTS FOR SUBSTANCES   
IN SCHEDULES II, III AND IV   
OF THE CONVENTION ON PSYCHOTROPIC SUBSTANCES OF 1971**

**(to be furnished to the International Narcotics Control Board (INCB) pursuant to  
Economic and Social Council resolutions 1981/7, 1991/44, 1993/38 and 1996/30)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Country or Territory:** |  | **Date:** |  |
| **Competent office:** |  | | |
| **Title or function:** |  | | |
| **Responsible officer’s name:** |  | **Email:** |  |
| **Telephone number(s):** |  | **Fax number(s):** |  |
| **Signature:** |  | | |
| **These assessments should be effective as of:** | | | |

**This form can also be downloaded from the INCB website at:   
www.incb.org, under “Psychotropic Substances/Toolkit/Form B/P and Supplement”**

**Please consider submitting this form using XML format.**

This form should be completed and sent to:

International Narcotics Control Board

Vienna International Centre

P.O. Box 500, 1400 Vienna, Austria

Telephone: + (43) (1) 26060-4277 Facsimile: + (43) (1) 26060-5867 or 26060-5868

Email: incb.secretariat@un.org, incb.psychotropics@un.org Home page: [www.incb.org](http://www.incb.org)

### Total quantities required annually for medical and scientific purposes

Form B/P may be used to submit assessments for all psychotropic substances to be used in the country. Assessments should reflect the total domestic medical and scientific requirements for   
one year. They should therefore include quantities to be manufactured domestically and not be restricted to imports. Quantities needed for industrial purposes (i.e. to manufacture other substances) should be included and the purposes should be indicated (i.e. qualitative and quantitative information on final products). The assessments should further include requirements to be held in stock to meet exceptional circumstances. Quantities required for exports or re-exports should not be included in the assessments.

All Governments are encouraged to provide information on the method used to determine the assessments furnished in Form B/P. In this context, the ***Guide on Estimating Requirements for Substances under International Control***, available at www.incb.org, might be useful. The *Guide* is intended to assist competent national authorities in identifying methods for calculating the quantities of controlled substances required for medical and scientific purposes and may assist authorities in preparing the assessments of annual requirements for psychotropic substances.

Unlike estimates for narcotic drugs, the assessments for psychotropic substances are not required to be confirmed by the International Narcotics Control Board (INCB).

INCB recommends that a revised Form B/P be submitted at least once every three years. INCB will use reported assessments for reference during a three-year period unless a supplement to previously submitted assessments is received. The quantities indicated on Form B/P will be used as a guide by the authorities responsible for authorizing exports in exporting countries.

Assessments are updated on a weekly basis and placed on the INCB website at: [www.incb.org](http://www.incb.org), under “Psychotropic Substances/Status of Assessments”.

**STATEMENT OF THE METHOD**

Please provide here comments on the methods used in determining   
the various assessments reported on this form and/or any changes.

**Remarks**

**Assessments of requirements for substances in Schedule II**

|  |  |  |  |
| --- | --- | --- | --- |
| *Code* | *Substance* | *Kilograms* | *Grams* |
| PA 003 | Amfetamine |  |  |
| PA 007 | Amineptine |  |  |
| PA 008 | AM-2201 |  |  |
| PA 009 | 5F-APINACA (5F-AKB-48) |  |  |
| PA 010 | 5F-AMB-PINACA (5F-AMB, 5F-MMB-PINACA) |  |  |
| PB 008 | 2C-B |  |  |
| PC 011 | AB-CHMINACA |  |  |
| PC 012 | CUMYL-4CN-BINACA |  |  |
| PC 013 | ADB-CHMINACA |  |  |
| PC 014 | 4-CMC (4-chloromethcathinone; clephedrone) |  |  |
| PD 002 | Dexamfetamine |  |  |
| PD 010 | *delta*-9-THC\* |  |  |
| PE 007 | Ethylone |  |  |
| PE 008 | Ethylphenidate |  |  |
| PF 005 | Fenetylline |  |  |
| PF 007 | 4-fluoroamphetamine (4-FA) |  |  |
| PF 008 | FUB-AMB |  |  |
| PF 009 | ADB-FUBINACA |  |  |
| PF 010 | AB-FUBINACA |  |  |
| PG 002 | GHB |  |  |
| PJ 001 | JWH-018 |  |  |
| PL 006 | Levamfetamine |  |  |
| PL 007 | Levomethamphetamine |  |  |
| PM 002 | Mecloqualone |  |  |
| PM 005 | Metamfetamine |  |  |
| PM 006 | Methaqualone |  |  |
| PM 007 | Methylphenidate |  |  |
| PM 015 | Metamfetamine racemate |  |  |
| PM 021 | MDPV (3,4-methylenedioxypyrovalerone) |  |  |
| PM 022 | Mephedrone (4-methylmethcathinone) |  |  |
| PM 023 | Methylone (*beta*-keto-MDMA) |  |  |
| PM 024 | Methoxetamine (MXE) |  |  |
| PM 025 | MDMB-CHMICA |  |  |
| PM 026 | Methiopropamine (MPA) |  |  |
| PM 027 | 4-methylethcathinone (*4-MEC*) |  |  |
| PM 028 | 5F-MDMB-PICA (5F-MDMB-2201) |  |  |
| PM 029 | 4-F-MDMB-BINACA |  |  |
| PN 009 | *N*-benzylpiperazine (BZP) |  |  |
| PN 010 | *N*-ethylnorpentylone (ephylone) |  |  |
| PN 011 | N-ethylhexedrone |  |  |
| PP 005 | Phencyclidine |  |  |
| PP 006 | Phenmetrazine |  |  |
| PP 011 | 5F-ADB/5F-MDMB-PINACA |  |  |
| PP 018 | AB-PINACA |  |  |
| PP 022 | *α*-PVP |  |  |
| PP 023 | 4,4’-DMAR |  |  |
| PP 025 | Pentedrone |  |  |
| PP 026 | 5F-PB-22 |  |  |
| PP 027 | *alpha-*PHP |  |  |
| PS 001 | Secobarbital |  |  |
| PU 001 | UR-144 |  |  |
| PX 001 | XLR-11 |  |  |
| PZ 001 | Zipeprol |  |  |

\* This refers to *delta*-9-tetrahydrocannabinol and its stereochemical variants of synthetic origin. Information on   
*delta*-9-tetrahydrocannabinol originating from the cannabis plant (Indian hemp) should be furnished as a narcotic drug in   
Form B (Annual estimates of requirements of narcotic drugs, manufacture of synthetic drugs, opium production and cultivation of the opium poppy for purposes other than opium production) in terms of cannabis, cannabis resin or cannabis extract

#### Assessments of requirements for substances in Schedule III

|  |  |  |  |
| --- | --- | --- | --- |
| *Code* | *Substance* | *Kilograms* | *Grams* |
| PA 002 | Amobarbital |  |  |
| PB 004 | Butalbital |  |  |
| PB 006 | Buprenorphine |  |  |
| PC 001 | Cyclobarbital |  |  |
| PC 009 | Cathine |  |  |
| PF 002 | Flunitrazepam |  |  |
| PG 001 | Glutethimide |  |  |
| PP 002 | Pentobarbital |  |  |
| PP 014 | Pentazocine |  |  |

Assessments of requirements for substances in Schedule IV

|  |  |  |  |
| --- | --- | --- | --- |
| *Code* | *Substance* | *Kilograms* | *Grams* |
| PA 001 | Amfepramone |  |  |
| PA 004 | Alprazolam |  |  |
| PA 005 | Allobarbital |  |  |
| PA 006 | Aminorex |  |  |
| PB 001 | Barbital |  |  |
| PB 002 | Benzfetamine |  |  |
| PB 003 | Bromazepam |  |  |
| PB 005 | Butobarbital |  |  |
| PB 007 | Brotizolam |  |  |
| PC 002 | Camazepam |  |  |
| PC 003 | Chlordiazepoxide |  |  |
| PC 004 | Clobazam |  |  |
| PC 005 | Clonazepam |  |  |
| PC 006 | Clorazepate |  |  |
| PC 007 | Clotiazepam |  |  |
| PC 008 | Cloxazolam |  |  |
| PD 005 | Delorazepam |  |  |
| PD 006 | Diazepam |  |  |
| PE 001 | Ethchlorvynol |  |  |
| PE 002 | Ethinamate |  |  |
| PE 003 | Estazolam |  |  |
| PE 004 | Ethyl loflazepate |  |  |
| PE 005 | Etilamfetamine |  |  |
| PE 009 | Etizolam |  |  |
| PF 001 | Fludiazepam |  |  |
| PF 003 | Flurazepam |  |  |
| PF 004 | Fencamfamin |  |  |
| PF 006 | Fenproporex |  |  |
| PF 011 | Flualprazolam |  |  |
| PH 001 | Halazepam |  |  |
| PH 002 | Haloxazolam |  |  |
| PK 001 | Ketazolam |  |  |
| PL 001 | Lefetamine, SPA |  |  |
| PL 003 | Loprazolam |  |  |
| PL 004 | Lorazepam |  |  |
| PL 005 | Lormetazepam |  |  |
| PM 001 | Mazindol |  |  |
| PM 003 | Meprobamate |  |  |
| PM 008 | Methylphenobarbital |  |  |
| PM 009 | Methyprylon |  |  |
| PM 010 | Medazepam |  |  |
| PM 012 | Mefenorex |  |  |
| PM 016 | Midazolam |  |  |
| PM 018 | Mesocarb |  |  |
| PN 001 | Nimetazepam |  |  |
| PN 002 | Nitrazepam |  |  |
| PN 003 | Nordazepam |  |  |
| PO 001 | Oxazepam |  |  |
| PO 002 | Oxazolam |  |  |
| PP 004 | Phendimetrazine |  |  |
| PP 008 | Phenobarbital |  |  |
| PP 009 | Phentermine |  |  |
| PP 010 | Pipradrol |  |  |
| PP 015 | Pinazepam |  |  |
| PP 016 | Prazepam |  |  |
| PP 019 | Pyrovalerone |  |  |
| PP 020 | Pemoline |  |  |
| PP 024 | Phenazepam |  |  |
| PS 003 | Secbutabarbital |  |  |
| PT 003 | Temazepam |  |  |
| PT 004 | Tetrazepam |  |  |
| PT 005 | Triazolam |  |  |
| PV 001 | Vinylbital |  |  |
| PZ 002 | Zolpidem |  |  |